XR 311

Drug Profile

XR 311

Alternative Names: HN 66000; KSB 311M; KSB 311N; KSB 311P; KSB 311R; PEP04; Project KSB311R; SOT-107; TF CRM 107; Transferrin-CRM 107; TransMID; TransMID 107M; TransMID 107N; TransMID 107P; TransMID 107R

Latest Information Update: 03 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GE Healthcare; National Institutes of Health (USA)
  • Developer Nycomed; Sosei; Xenova Group
  • Class Antineoplastics; Drug conjugates; Immunotoxins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; CNS cancer

Highest Development Phases

  • Discontinued CNS cancer; Glioblastoma; Glioma

Most Recent Events

  • 19 Apr 2005 Xenova has licensed XR 311 to PharmaEngine in the Republic of China and in the Republic of South Korea
  • 14 Feb 2005 XR 311 has received orphan drug status for glioma in Japan
  • 07 Jul 2004 Phase-III clinical trials in Glioblastoma in European Union (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top